$37.93
+1.39 (+3.80%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where IDYA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
10 interventional
Held by 11 tracked-famous managers (Qube Research & Technologies Ltd, CITADEL ADVISORS LLC, Balyasny Asset Management L.P., Man Group plc, Verition Fund Management LLC, +6 more) · FINRA short interest 13.2 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Neoadjuvant Darovasertib in Primary Uveal MelanomaNCT07015190Cohort 1: To demonstrate that the proportion of subjects with vision loss is lower for subjects in the Treatment Arm vs the Control ArmRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Darovasertib · Procedure: Primary Local Therapy | Uveal Melanoma | 520 | Oct 2030 | ≤ 1,534 d | 2026-05-06 |
| A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid TumorsNCT07540572Safety and Tolerability of IDE574 in Part 1 A Monotherapy Dose escalationNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: IDE574, Fulvestrant injection | ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC), Microsatellite Stable (MSS) Colorectal Carcinoma | 160 | 2030-03-30 | in 1,319 d | 2026-06-16 |
| A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung CancerNCT07174583Part 1A: Safety and Tolerability of IDE849 (Monotherapy)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: IDE849, durvalumab, IDE161, Carboplatin | Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3 | 262 | Jul 2029 | ≤ 1,077 d | 2026-07-09 |
| A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid TumorsNCT07277413Incidence of Dose-limiting Toxicities (DLTs) of IDE892 (Parts 1 and 3)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: IDE892, IDE397 | NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (UC), Bladder Cancer, Mesothelioma, Pleural Mesothelioma, Peritoneal Mesothelioma, Non-Small Cell Lung Cancer NSCLC, Pancreatic Cancer, Biliary Tract Carcinoma | 260 | 2028-04-30 | in 620 d | 2026-08-05 |
| A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesNCT07503808Safety and tolerability of IDE034 in Part 1 dose escalationNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: IDE034 | Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Castration-resistant Prostate Cancer, Non Small Cell Lung Cancer, Endometrium Cancer, Triple Negative Breast Cancer | 150 | 2027-07-30 | in 345 d | 2026-06-18 |
| (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular MelanomaNCT05907954Incidence of Adverse Events (AEs) and significant laboratory abnormalitiesOpen-label · Treatment | Phase 2 | Active, not recruiting | Drug: Darovasertib | Uveal Melanoma | 160 | 2027-04-30 | in 254 d | 2026-03-16 |
| Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC FusionsNCT03947385Dose-limiting Toxicity (DLT)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: IDE196, Binimetinib, Crizotinib | Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors | 336 | 2027-01-29 | in 163 d | 2026-06-08 |
| IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaNCT05987332Phase 2a: To determine the optimal dose of IDE196 + Crizotinib combination for Phase 2B and Phase 3 by evaluating the following:Randomized · Open-label · Treatment | Phase 2/3 | Active, not recruiting | Drug: IDE196, Crizotinib, Pembrolizumab, Ipilimumab, Nivolumab, Dacarbazine | Metastatic Uveal Melanoma | 420 | 2027-01-15 | in 149 d | 2026-02-17 |
| Study of IDE397 in Participants With Solid Tumors Harboring MTAP DeletionNCT04794699Dose-limiting Toxicities (DLTs) of IDE397Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: IDE397, Sacituzumab govitecan | Solid Tumor | 169 | 2027-01-07 | in 141 d | 2026-04-09 |
| A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsNCT05787587Part 1 (Dose Escalation): To characterize the safety and tolerability of IDE161 monotherapy or in combination with pembrolizumab to determine the MTD and/or RDENon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: IDE-161, Pembrolizumab | Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Extensive Stage Small Cell Lung Cancer (ES-SCLC), NSCLC | 216 | Oct 2026 | ≤ 73 d | 2026-07-13 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19